Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases as Antibiofilm Agents in Acute Pulmonary Pseudomonas aeruginosa Infection

Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0005222. doi: 10.1128/aac.00052-22. Epub 2022 Jul 7.

Abstract

The bacterium Pseudomonas aeruginosa can colonize the airways of patients with chronic lung disease. Within the lung, P. aeruginosa forms biofilms that can enhance resistance to antibiotics and immune defenses. P. aeruginosa biofilm formation is dependent on the secretion of matrix exopolysaccharides, including Pel and Psl. In this study, recombinant glycoside hydrolases (GHs) that degrade Pel and Psl were evaluated alone and in combination with antibiotics in a mouse model of P. aeruginosa infection. Intratracheal GH administration was well tolerated by mice. Pharmacokinetic analysis revealed that, although GHs have short half-lives, administration of two GHs in combination resulted in increased GH persistence. Combining GH prophylaxis and treatment with the antibiotic ciprofloxacin resulted in greater reduction in pulmonary bacterial burden than that with either agent alone. This study lays the foundation for further exploration of GH therapy in bacterial infections.

Keywords: Pel; Pseudomonas aeruginosa; Psl; acute pulmonary infection; antibiotic; antimicrobial combinations; bacteria; biofilm; exopolysaccharide; glycoside hydrolase (GH).

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Biofilms
  • Glycoside Hydrolases / metabolism
  • Lung / metabolism
  • Mice
  • Polysaccharides, Bacterial / metabolism
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas Infections* / microbiology
  • Pseudomonas aeruginosa / metabolism

Substances

  • Anti-Bacterial Agents
  • Polysaccharides, Bacterial
  • Glycoside Hydrolases